AU2005254790B2 - Purine nucleotide derivatives - Google Patents

Purine nucleotide derivatives Download PDF

Info

Publication number
AU2005254790B2
AU2005254790B2 AU2005254790A AU2005254790A AU2005254790B2 AU 2005254790 B2 AU2005254790 B2 AU 2005254790B2 AU 2005254790 A AU2005254790 A AU 2005254790A AU 2005254790 A AU2005254790 A AU 2005254790A AU 2005254790 B2 AU2005254790 B2 AU 2005254790B2
Authority
AU
Australia
Prior art keywords
camps
mmol
adenosine
cyclic
camp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005254790A
Other languages
English (en)
Other versions
AU2005254790A1 (en
Inventor
Vidar Bjornstad
Jo Klaveness
Geir Langli
Kjetil Tasken
Kjell Undheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolog Life Science Institute Forschungslabor und Biochemica Vertrieb GmbH
Original Assignee
Biolog Life Science Institute Forschungslabor und Biochemica Vertrieb GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolog Life Science Institute Forschungslabor und Biochemica Vertrieb GmbH filed Critical Biolog Life Science Institute Forschungslabor und Biochemica Vertrieb GmbH
Publication of AU2005254790A1 publication Critical patent/AU2005254790A1/en
Application granted granted Critical
Publication of AU2005254790B2 publication Critical patent/AU2005254790B2/en
Assigned to SOLVELL AS reassignment SOLVELL AS Request for Assignment Assignors: LAURAS AS
Assigned to BIOLOG LIFE SCIENCE INSTITUTE GMBH reassignment BIOLOG LIFE SCIENCE INSTITUTE GMBH Request for Assignment Assignors: SOLVELL AS
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2005254790A 2004-06-18 2005-06-20 Purine nucleotide derivatives Ceased AU2005254790B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0413726.1A GB0413726D0 (en) 2004-06-18 2004-06-18 Compounds
GB0413726.1 2004-06-18
PCT/GB2005/002418 WO2005123755A2 (en) 2004-06-18 2005-06-20 Purine nucleotide derivatives

Publications (2)

Publication Number Publication Date
AU2005254790A1 AU2005254790A1 (en) 2005-12-29
AU2005254790B2 true AU2005254790B2 (en) 2012-02-23

Family

ID=32750205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005254790A Ceased AU2005254790B2 (en) 2004-06-18 2005-06-20 Purine nucleotide derivatives

Country Status (10)

Country Link
US (1) US8153609B2 (enExample)
EP (1) EP1765844B1 (enExample)
JP (1) JP5044750B2 (enExample)
CN (1) CN101001865A (enExample)
AU (1) AU2005254790B2 (enExample)
CA (1) CA2568907C (enExample)
DK (1) DK1765844T3 (enExample)
ES (1) ES2496946T3 (enExample)
GB (1) GB0413726D0 (enExample)
WO (1) WO2005123755A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006544A2 (en) * 2005-07-12 2007-01-18 Vrije Universiteit Brussel Cyclic adenosine monophosphate compounds for the treatment of immune-related disorders
GB0618235D0 (en) * 2006-09-15 2006-10-25 Lauras As Process
SI2448968T1 (sl) * 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2022216577A1 (en) * 2021-04-09 2022-10-13 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
US20240352056A1 (en) 2021-09-06 2024-10-24 Mireca Medicines Gmbh Improved methods for production of cyclic guanosine-monophosphate analogues

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3968101A (en) 1974-12-20 1976-07-06 Icn Pharmaceuticals, Inc. 8-Substituted cyclic nucleotides by free radical alkylation and acylation
WO1989007108A1 (en) * 1988-02-01 1989-08-10 Bernd Jastorff Process for producing nucleoside-3',5'-cyclophosphates and nucleoside-3',5'-cyclothiophosphates
AU4226693A (en) 1992-05-01 1993-11-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Phosphorothioate derivatives of cyclic AMP analogues
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
NO971997D0 (no) 1997-04-29 1997-04-29 Kjetil Tasken Bruk av immunmodulerende midler

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104250A1 (en) * 2002-06-07 2003-12-18 Kylix, B. V. New compounds for modulating the activity of exchange proteins directly activated by camp (epacs)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clayden, J. et al., "Organic Chemistry", Oxford University Press, Oxford, 2001, chapter 48, pages 1324-1332. *
X-B. Tian et al., Progress in Natural Science, 1994, 4 (6), 726-731. *

Also Published As

Publication number Publication date
EP1765844A2 (en) 2007-03-28
WO2005123755A3 (en) 2006-04-06
EP1765844B1 (en) 2014-07-30
AU2005254790A1 (en) 2005-12-29
CA2568907C (en) 2015-06-09
JP5044750B2 (ja) 2012-10-10
GB0413726D0 (en) 2004-07-21
ES2496946T3 (es) 2014-09-22
CA2568907A1 (en) 2005-12-29
WO2005123755A2 (en) 2005-12-29
DK1765844T3 (da) 2014-09-01
US8153609B2 (en) 2012-04-10
US20080293665A1 (en) 2008-11-27
CN101001865A (zh) 2007-07-18
JP2008502673A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
AU2012223012B2 (en) Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
CN103987712B (zh) 2’，3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药
EP2752422B1 (en) Stereoselective synthesis of phosphorus containing actives
EP3546473B1 (en) Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
US20100137576A1 (en) 5' o [(n acyl)amidophosphate] and 5' o [(n acyl)amidothiophosphate] and 5' o [(n acyl)amidodithiophosphate] and 5' o [(n acyl)amidoselenophosphate] derivatives of nucleosides and processes for the manufacture thereof
EP1765844B1 (en) Purine nucleotide derivatives
EP0836613A1 (en) Water-soluble adenosine kinase inhibitors
JP3142874B2 (ja) ３´−置換ヌクレオシド誘導体
US20110092694A1 (en) Synthesis of 5-azacytidine
EP0671410A1 (en) Antiviral compounds
JPH09504541A (ja) ５‐フルオロウラシル誘導体
Revankar et al. Synthesis and antiviral activity of certain 5'-monophosphates of 9-D-arabinofuranosyladenine and 9-D-arabinofuranosylhypoxanthine
CN110678473A (zh) 核苷类抗癌药或抗病毒药的5’位二苄基单磷酸酯衍生物
Raju et al. Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-. beta.-D-ribofuranosyl analogs of AMP, GMP, IMP, and CMP
Patil et al. Synthesis and biological activity of a novel adenosine analog 3-. beta.-D-ribofuranosylthieno [2, 3-d] pyrimidin-4-one
WO1996001834A1 (en) 2'-deoxy-2'-(substituted or unsubstituted methylidene)-4'-thionucleoside
EP1620451A2 (en) Industrially scalable nucleoside synthesis
US5420115A (en) Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides
CN111836823A (zh) β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法
Lang et al. Synthesis of 8-vinyladenosine 5′-di-and 5′-triphosphate: evaluation of the diphosphate compound on ribonucleotide reductase
Perlíková Synthesis of novel cytostatic deazapurine nucleosides and pronucleotides
JPH02188A (ja) ヌクレオチド類縁体およびその製造法，ならびに抗ウイルス剤
HK1181775B (en) Stereoselective synthesis of phosphorus containing actives
JPWO1999043690A1 (ja) Ｌ−４′−チオアラビノフラノヌクレオシド化合物およびそれを含む医薬組成物
PL202608B1 (pl) 5'-O-(amidotiofosforano)-i 5'-O-(amidoditiofosforano)nukleozydy (54) oraz sposób wytwarzania 5'-O-(amidofosforano)-,5'-O-(amidotiofosforano)- i 5'-O-(amidoditiofosforano)nukleozydów

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SOLVELL AS

Free format text: FORMER APPLICANT(S): LAURAS AS

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BIOLOG LIFE SCIENCE INSTITUTE GMBH

Free format text: FORMER OWNER WAS: SOLVELL AS

MK14 Patent ceased section 143(a) (annual fees not paid) or expired